Abstract. The size of affibody molecules makes them suitable as targeting agents for targeted radiotherapy with the ·-emitter 211 At, since their biokinetic properties match the short physical half-live of 211 At. In this study, the potential for this approach was investigated in vivo. Two different HER-2 binding affibody molecules were radiolabeled with 211 At using both the linker PAB (N-succinimidyl-para-astatobenzoate) and a decaborate-based linker, and the biodistribution in tumorbearing nude mice was investigated. The influence of L-lysine and Na-thiocyanate on the 211 At uptake in normal tissues was also studied. Based on the biokinetic information obtained, the absorbed dose was calculated for different organs. Compared with a previous biodistribution with 125 I, the 211 At biodistribution using the PAB linker showed higher uptake in lungs, stomach, thyroid and salivary glands, indicating release of free 211 At. When the decaborate-based linker was used, the uptake in those organs was decreased, but instead, high uptake in kidneys and liver was found. The uptake, when using the PAB linker, could be significantly reduced in some organs by the use of L-lysine and/or Na-thiocyanate. In conclusion, affibody molecules have suitable blood-kinetics for targeted radionuclide therapy with 211 At. However, the labeling chemistry affects the distribution in normal organs to a high degree and needs to be improved to allow clinical use.
Introduction
Targeted radionuclide therapy is a promising way of treating cancer, especially when disseminated tumor cells and micrometastases are present. Various targeting agents, directed against a number of tumor-associated antigens, have been developed. However, the radionuclides used are mainly ß-emitters, such as 131 I and 90 Y, which deposit their energy over a long distance [0.8 mm for 131 I and 5.3 mm for 90 Y (1)]. To be therapeutically effective, ß-emitters are dependent on cross-fire irradiation, which might result in dose-limiting toxicity to non-target tissues, such as bone marrow. If small cell clusters or single cells are to be effectively treated, radionuclides that deposit their energy within one or a few cell diameters, such as ·-emitters, are required (1) . The problems with ·-emitters are that they are quite short-lived, and not commercially available (2) . The most commonly used ·-emitters for radionuclide therapy are 212 Bi, 213 Bi and 211 At. Of those, 211 At has the longest physical half-life, 7.2 h compared with 61 and 46 min, respectively for the Bi isotopes. Such short physical half-lives result in most decays occurring in the blood stream, before reaching the tumor. Therefore, it is important that the targeting agent finds its target fast. Peptides and small proteins, which have fast pharmacokinetics, are thus preferable for therapy with short-lived ·-emitters.
We recently developed and evaluated a new type of targeting agent, a tumor targeting affibody molecule (3, 4) . The affibody molecules investigated, Z HER2:4 and its bivalent version (Z HER2:4 ) 2 , are directed against the membrane protein HER-2 (K D = 50 and 3 nM, respectively), which is overexpressed in many breast and ovarian carcinomas, but appear to a much lower extent in normal adult tissue (5, 6) . The small size (7 kDa for the monovalent-, and 15 kDa for the bivalent affibody molecule) and high stability of the protein make it an interesting targeting agent for radionuclide therapy. The affibody molecule (Z HER2:4 ) 2 can be radiolabeled with both 125 2 (PAB = N-succinimidyl-para-astatobenzoate and PIB = N-succinimidyl-para-iodobenzoate) respectively. From previous experiments we know that the radioiodinated form resulted in a tumor-to-blood ratio of ~10 at 8-h post injection. The plasma half-life in the elimination phase was ~45 min (7) . This time pattern should suite the physical half-life of 211 At (7.2 h).
Affinity maturation of the original HER-2 binding affibody molecule Z HER2:4 was recently described (8) . The affinity maturated affibody molecule, Z HER2:342 , shows a remarkably high affinity (K D = 22 pM) for HER-2 and its non-radioactive form has stronger growth inhibiting properties compared with the previously studied affibody molecules (9) .
In this study, two different HER-2 binding affibody molecules were labeled with 211 At and investigated in vivo. The therapeutic potential is discussed.
Materials and methods
Preparation of the B10 maleimide. Preparation of the decaborate-based linker molecule for site-specific thiolcoupled radiolabeling is described schematically in Fig. 1 . (Et 3 NH)B 10 H 9 -CO (1) (10) was coupled to trioxadimine (2) . The resulting (Et 3 NH)B 10 H 9 -CO-trioxadiamine (3) was then conjugated to NHS-3-Maleimido-propionate (Quanta BioDesign, Powell, OH, USA) (4). The final product, the decaborate linker (5), was confirmed using NMR spectroscopy and mass spectrometry.
Radiolabeling. The
211 At was produced at Rigshospitalet, Copenhagen, Denmark, as described by Persson et al (11) and the astatine was separated from the target using dry distillation at our laboratory. The astatine was eluted in chloroform, which was evaporated under a gentle flow of argon gas. The 211 At was then dissolved in 10 μl acetic acid (0.1% in water) immediately before labeling.
PAB (N-succinimidyl-para-astatobenzoate) labeling was achieved using the precursor N-succinimidyl-para-(trimethylstannyl) benzoate, prepared according to Koziorowski et al (12) . Immediately before labeling, it was dissolved in 5% acetic acid in methanol to a concentration of 1 mg/ml and 5 μl was added to a vial containing 211 At dissolved in 0.1% acetic acid. Addition of 10 μl chloramine-T (4 mg/ml in water; Sigma, St. Louis, MO, USA) started the reaction. After 5 min of constant shaking, the reaction was terminated by addition of 10 μl sodium meta-bisulphite (8 mg/ml in water; Aldrich, Steinheim, Germany). The astatinated linker molecule was then coupled to 60 μg of Z HER2:342 -cys or (Z HER2:4 ) 2 (2.4 mg/ml or 1.2 mg/ml in phosphate buffered saline (PBS), Affibody AB, Bromma, Sweden) by addition of 100 μl 0.07 M borate buffer (pH 9.4) followed by 45 min continuous shaking in room temperature. The astatinated affibody molecules, [
211 At]PAB-Z HER2:342 -cys and [
211 At]PAB-(Z HER2:4 ) 2 , were then separated from free 211 At using gel filtration on a NAP-5 column (Amersham Biosciences, Uppsala, Sweden) equilibrated in PBS. The specific activities obtained varied between 0.3-3 MBq/μg.
The decaborate-based linker molecule (number 5 in Fig. 1 ), [13' -(N'-[3''-(maleimido)propionylamino]-4',7',10'-trioxatridecaneamino)-nonahydro-closo-decaborate carboxylic acid triethylammonium salt], was dissolved in dimethyl formamide to a concentration of 10 mg/ml and 3 μl was added to a vial containing 211 At dissolved in 0.1% acetic acid. Radiolabeling of the linker molecule was then performed as described above. Animals. Female BALB/c nu/nu mice (18-23 g, Møllegaard, Denmark) were used in the tumor model, whereas female NMRI mice (24-27 g, B&K Universal, Sollentuna, Sweden) were used in the normal model. Intravenous (i.v.) injections were made via the tail vein. At the end of the experiments, the mice were anesthetized with a mixture of Ketalar and Rumpun and euthanized by heart puncture. Organs of interest were collected, weighed, and the Á-component of the decay was measured in an automated gamma counter (1480 Wizard, Wallac, Finland). Injected dose was calculated as the radioactivity in the control syringes subtracted by the radioactivity left in the tail and in the syringe.
Biodistribution of [
211 At]PAB-(Z HER2:4 ) 2 . BALB/c mice were injected, subcutaneously (s.c.) in the right flank, with 1.7x10 7 SKOV-3 cells in 100 μl McCoy's 5A culture medium, supplemented with 10% bovine serum albumin, 2 mM L-glutamine and PEST (100 IU/ml penicillin, 100 μg/ml streptomycin), all from Biochrom KG (Berlin, Germany). One month later, when the tumor weight was ~100 mg, the mice were randomized into groups of four. All mice were injected i.v. with 50 μl (250 ng, ~700 kBq) [
211 At]PAB-(Z HER2:4 ) 2 . Forty minutes before injection of [ 211 At]PAB-(Z HER2:4 ) 2 , one group of mice (blocked) was injected with 100 μg unlabeled (Z HER2:4 ) 2 in PBS s.c. in the neck to block the specific uptake of the radiolabeled compound. After 1, 4, 7, 14 and 21 h respectively (after 7 h also the blocked group), mice were euthanized and dissected, as described above. Percent injected dose per gram tissue (%ID/g) was calculated for all organs. For the thyroid, a standard weight of 5 mg for a 20 g mouse was used for calculations.
211 At]B10-Z HER2:342 -cys. Four NMRI mice were injected i.v. with 100 μl (1.4 μg, 11 kBq) [
211 At]B10-Z HER2:342 -cys. Four hours later, the animals were sacrificed, and the organs were collected and weighted. The radioactivity in the isolated tissues was measured and %ID/g was calculated, as described above. The HER-2 binding capacity of the astatinated affibody was also tested on SKOV-3 cells in vitro. SKOV-3 cells (~200 000) were seeded in 3-cm culture dishes and the following day, ~40 ng of the astatinated affibody per dish was added to 6 dishes. To 3 of the dishes, an excess (~2 μg per dish) of unlabeled Z HER2:342 was added to block the specific uptake.
Prevention of deastatination and astatide uptake. Sixteen NMRI mice were injected i.v. with 100 μl ( 211 At]PAB-Z HER2:342 -cys (after 4 h the blocked group was also taken). Organs and tissues of interest were collected and %ID/g was then calculated, as described above.
Statistical test. The Student's t-test was used to test the differences in tissue concentration of radioactivity, between different groups of animals. The level of significance was set at p<0.05.
Dosimetry calculations.
In order to investigate the potential for a therapy study in mice, a dosimetry calculation was performed. The organ uptake values from the biodistribution of [
211 At]PAB-Z HER2:342 -cys, non-corrected for physical half-life, were integrated over time to obtain the residence time per gram tissue for dosimetry calculations. Integration between time zero and 16 h was made by the trapezoid method. The two last time points were fitted to a single exponential function, which was used to estimate the residence time from 16 h to infinity. Except for the thyroid and stomach, the value of the extrapolated area was small in all organs compared to the area obtained between time zero and 16 h.
To obtain an error estimate of the absorbed dose, the uptake values were randomly generated from a normal distribution with the mean and standard deviations obtained from the biodistribution of [
211 At]PAB-Z HER2:342 -cys. Using the experimental data, new uptake values were randomly generated with the assumption of a normal distribution. A set of 30 randomly produced uptake curves were then integrated as described above. This created a set of 30 randomly distributed residence time values. The relative standard deviation of the absorbed dose was taken to be the same as for this set of data.
In 58.2% of the 211 At decays, 211 Po (T 1/2 = 0.516 sec) is produced. Due to its short half-life, 211 Po is from a dosimetric point of view regarded to be in equilibrium with 211 At. The second branch of the 211 At-decay produces 207 Bi (T 1/2 = 34.4 a). Due to the long half-life and the low S-value for 207 Bi in relation to the 211 At/ 211 Po-decay, it does not significantly contribute to the absorbed dose and is neglected in the dosimetry calculations. S-values for 211 At and 211 Po were obtained from RADAR phantoms (Unit Density Spheres) (http://www.doseinfo-radar.com/RADARphan.html). These values were summarized, taken into account the decay abundance, to obtain a value of 1.09 mGy/(MBqxs) in one gram tissue. This value was multiplied with the organ residence values to obtain the organ absorbed dose. This simple dosimetry calculation is motivated by the fact that the main absorbed dose from the two radionuclides are given locally by the ·-particles. Photons and other penetrating radiations are only contributing to a slight extent, which means that the cross-talk between different organs is negligible. concentrations were seen in many organs, especially the lungs, spleen, stomach and salivary glands where significantly higher radionuclide concentrations were obtained with 211 At than in the earlier study with 125 I. In those organs, the uptake appeared to peak at the 4-h time-point, where 25-55 times more 211 At was found, compared with 125 I. As seen in Fig. 3 , the amount of radioactivity in the tumor at 7-h post injection could be displaced by administration of unlabeled (Z HER2:4 ) 2 , indicating receptor-specific tumor uptake.
Results

Biodistribution of [ 211 At]PAB-(Z HER2
:
Biodistribution of [
211 At]B10-Z HER2:342 -cys. When the PAB linker molecule was exchanged for the decaborate-based B10, the high concentration of radioactivity in the lungs, stomach and salivary glands was markedly reduced, as seen in Fig. 4 . However, the concentration in the spleen was not reduced, and the concentrations in liver and kidneys were markedly increased with the decaborate-based linker (6 times higher in the liver and 25 times higher in the kidneys). The thyroid uptake was somewhat reduced, but was still higher than the corresponding uptake of 125 I using the PIB linker (1). A binding test of [
211 At]B10-Z HER2:342 -cys on SKOV-3 cells in vitro, according to a method described in Wikman et al (4) , showed that the astatinated affibody bound to the cells in a specific manner (data not shown).
Prevention of deastatination and astatide uptake. As seen in Fig. 5 , the addition of L-lysine reduced the concentration of radioactivity, after administration of [
211 At]PAB-(Z HER2:4 ) 2 , in stomach and salivary glands. However, the reduction was not significant in the salivary glands. Administration of sodium thiocyanate significantly reduced the uptake in stomach, salivary glands and thyroid and the combination of L-lysine and sodium thiocyanate reduced the uptake of 211 At even more.
Biodistribution of [ 211 At]PAB-Z HER2
:342 -cys. Fig. 6 shows the biodistribution of [
211 At]PAB-Z HER2:342 -cys in nude mice carrying xenografted SKOV-3 tumors when degradation in the kidneys were blocked by administration of L-lysine 30 min before, and 1, 2, and 3 h after injection of the radiolabeled conjugate. The uptake of free 211 At was also blocked, by administration of Na-thiocyanate 24h and 1 h before injection of [
211 At]PAB-Z HER2:342 -cys. As seen in Fig. 6 , the concentration of radioactivity in the tumor was constantly ~7 %ID/g during the first 8 h, but decreased significantly after 16 h. The con-centration in lungs and spleen was high (~13 %ID/g) and almost constant during the first 8 h. The concentration in the thyroid increased with time, and reached 38 %ID/g at the 16-h time-point. A Student's t-test comparing the tissue concentrations of radioactivity at the 4-h time-point between the group that received a large excess of unlabeled Z HER2:342 -cys to blockspecific binding, and the group without such a block, revealed that the tumor concentration was significantly lower (p<0.05) in the blocked group, see inserted plot in Fig. 6 . There was no significant difference in any other organ (data not shown).
Dosimetry calculations.
The results from the simplified dosimetry calculations are summarized in Table I . The tumor received ~2 Gy/MBq, whereas lungs and spleen received 4 Gy/MBq. The thyroid received the highest dose, ~17 Gy/ MBq.
Discussion
The potential of the ·-emitter 211 At in targeted radiotherapy for treatment of metastasized malignancies and residual disease has been widely claimed (13, 14) . A prerequisite for therapy with a short-lived nuclide like 211 At (physical half-life 7.2 h) is that the target is reached within a few hours and that the remaining radioactivity is quickly removed from the system. This makes intact antibodies unsuitable for therapy with 211 At, but smaller antibody fragments, like scFv can still be considered. In this study, the potential for 211 At therapy using affibody molecules was investigated for the first time.
Our results with the astatinated (Z HER2:4 ) 2 shows that the biodistribution is markedly different from the previous biodistribution with the same compound labeled with 125 I. In most cases, the biodistribution of a protein radiolabeled with 125 I and 211 At are quite similar (11, 15, 16) , but there have been previous reported exceptions (17, 18) , especially when smaller molecules, such as antibody fragments have been used. The results from these studies, with high uptake in stomach, lungs and spleen, indicate that free 211 At is released in vivo. The high level of radioactivity in the tumor in the 211 At case is probably a result of higher blood levels, compared to the 125 I case. The tumor uptake can partly be explained by unspecific localization of 211 At, since only ~1/3 of the radioactivity in the tumor could be displaced by administration of unlabeled (Z HER2:4 ) 2 (Fig. 3) . For comparison, in the 125 I case, ~2/3 of the tumor uptake could be removed after blocking the specific uptake (1). However, the fact that some of the 211 At uptake could be displaced (Fig. 3 ) indicate at least some HER-2-specific tumor uptake of 211 At.
In a first approach to overcome this problem, a decaboratebased linker molecule was tested. It has been suggested that the release of free 211 At in vivo is a result of the C-At bond being weaker than the C-I bond, and that the problem might be solved using decaborate-based linker molecules instead of the benzamide derivates most often used, since the B-At bond is stronger than the C-At bond (19) . This hypothesis is strengthened by our study with [
211 At]B10-Z HER2:342 -cys. The high levels of radioactivity in lungs, stomach, thyroid and salivary glands were drastically reduced when the decaboratebased linker was used. However, a new problem was encountered, high uptake in the liver and kidneys, probably as a result of the residualizing properties of the decaboratebased linker.
The next approach was to go back to the PAB linker and evaluate methods to reduce the in vivo degradation and uptake of free 211 At. As seen in the biodistribution of [ 125 I]PIB-(Z HER2:4 ) 2 ( Fig. 2) (1) , the highest concentration of radioactivity was found in the kidneys. It is thus reasonable to assume that kidneys are a site of degradation. The radioactivity concentration in kidney can be reduced by blocking the re-absorption in proximal tubule by administration of L-lysine (20) , and hopefully, this approach would result in a decrease in release of free 211 At. We also tested if the uptake of free 211 At in normal tissues could be blocked by administration of sodium thiocyanate, as was done by Larsen et al (21) . We found that both L-lysine and Na-thiocyanate significantly reduced the uptake of 211 At in some normal tissues, and their combination was most efficient. The kidney uptake was, at the investigated time-point, not affected by L-lysine, but since there was a clear effect of L-lysine in stomach and thyroid, it is likely that the effect on the kidney was no longer detectable at the 4-h time-point. 211 At]PAB-Z HER2:342 -cys after co-administration of L-lysine and Na-thiocyanate. 
To determine if the second approach was good enough for testing in a therapeutic setting in mice, a full biodistribution in tumor-bearing mice was performed. Multiple time-points were analyzed, enabling estimation of absorbed dose for all organs. The effects of the L-lysine and Na-thiocyanate in this animal model were similar to those found in the normal mouse model, with a reduced uptake in stomach, salivary glands and thyroid. However, the concentrations in liver and spleen were higher at all time-points when L-lysine and Na-thiocyanate was administered. This was not observed in the results shown in Fig. 5 , and might be due to the fact that different affibody molecules were used. Surprisingly, the kidney concentrations were unaffected by the L-lysine at all time-points. Thus, the effects of the L-lysine administration cannot be explained by a decrease in kidney uptake of the radiolabeled compound, resulting in decreased degradation of the compound in the kidneys and release of free radiolabeling into the system, as previously discussed. The lack of effect of L-lysine on renal uptake of radiolabeling has been observed previously (22) and can possibly be explained by the already low kidney levels.
The dosimetry calculation showed that the thyroid received the highest radiation dose from 211 At, ~8 times more than the tumor. Also the lungs and spleen received a higher dose than the tumor, about twice that of the tumor. Liver and kidneys were exposed to about the same dose as the tumor. The lung is assumed to be a critical organ, making it imperative that the dose to the lungs must be further decreased before this approach can be applied in a therapeutic setting.
In conclusion, changing from one radiohalogen to another (i.e. from 125 I to 211 At), and/or changing linker molecule in the radiolabeling process, can result in dramatic changes in the biodistribution when small targeting agents, like affibody molecules, are used. The best solution found so far, when applying 211 At labeled affibody molecules for therapy, seems to be to use the PAB linker and to administer the conjugate in combination with L-lysine and Na-thiocyanate. However, the remaining problem with high concentrations of the radionuclide in e.g. lungs and spleen limits the use for this setting in radionuclide therapy. We believe that the high stability indicated when the decaborate-based linker molecules were used is essential for successful therapy, and further optimization in that field is now planned.
